As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Eli Lilly announced that its obesity therapy Zepbound delivered superior outcomes versus Novo Nordisk’s Wegovy across five ...

In secondary endpoints, 64.6% of participants using Zepbound saw 15% weight loss compared with 40.1% on Wegovy. And Zepbound participants saw their waists reduced by an average 7.2 in (18.4 cm), ...

Lilly's study showed that more patients treated with Zepbound had reductions in body weight of at least 10%, 15%, 20%, and 25% than those treated with Wegovy, while they also achieved a greater ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

It used to be that Chinese drug development was largely about creating "me too" drugs for the local market. But over the past ...